Targeting Toxins toward Tumors

Research output: Contribution to journalJournal articlepeer-review

Standard

Targeting Toxins toward Tumors. / Franzyk, Henrik; Christensen, Søren Brøgger.

In: Molecules, Vol. 26, No. 5, 1292, 2021.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Franzyk, H & Christensen, SB 2021, 'Targeting Toxins toward Tumors', Molecules, vol. 26, no. 5, 1292. https://doi.org/10.3390/molecules26051292

APA

Franzyk, H., & Christensen, S. B. (2021). Targeting Toxins toward Tumors. Molecules, 26(5), [1292]. https://doi.org/10.3390/molecules26051292

Vancouver

Franzyk H, Christensen SB. Targeting Toxins toward Tumors. Molecules. 2021;26(5). 1292. https://doi.org/10.3390/molecules26051292

Author

Franzyk, Henrik ; Christensen, Søren Brøgger. / Targeting Toxins toward Tumors. In: Molecules. 2021 ; Vol. 26, No. 5.

Bibtex

@article{fecfeb9bc4ff4dd09005a4fdc140fc0a,
title = "Targeting Toxins toward Tumors",
abstract = "Many cancer diseases, e.g., prostate cancer and lung cancer, develop very slowly. Commonchemotherapeutics like vincristine, vinblastine and taxol target cancer cells in their proliferating states.In slowly developing cancer diseases only a minor part of the malignant cells will be in a proliferativestate, and consequently these drugs will exert a concomitant damage on rapidly proliferating benigntissue as well. A number of toxins possess an ability to kill cells in all states independently of whetherthey are benign or malignant. Such toxins can only be used as chemotherapeutics if they can betargeted selectively against the tumors. Examples of such toxins are mertansine, calicheamicins andthapsigargins, which all kill cells at low micromolar or nanomolar concentrations. Advanced prodrugconcepts enabling targeting of these toxins to cancer tissue comprise antibody-directed enzymeprodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), lectin-directed enzymeactivated prodrug therapy (LEAPT), and antibody-drug conjugated therapy (ADC), which will bediscussed in the present review. The review also includes recent examples of protease-targetingchimera (PROTAC) for knockdown of receptors essential for development of tumors. In addition,targeting of toxins relying on tumor-overexpressed enzymes with unique substrate specificity willbe mentioned.",
keywords = "Faculty of Health and Medical Sciences, Prodrugs, Medicinal chemistry, Chemotherapy, Natural products, review article",
author = "Henrik Franzyk and Christensen, {S{\o}ren Br{\o}gger}",
year = "2021",
doi = "10.3390/molecules26051292",
language = "English",
volume = "26",
journal = "Molecules",
issn = "1420-3049",
publisher = "M D P I AG",
number = "5",

}

RIS

TY - JOUR

T1 - Targeting Toxins toward Tumors

AU - Franzyk, Henrik

AU - Christensen, Søren Brøgger

PY - 2021

Y1 - 2021

N2 - Many cancer diseases, e.g., prostate cancer and lung cancer, develop very slowly. Commonchemotherapeutics like vincristine, vinblastine and taxol target cancer cells in their proliferating states.In slowly developing cancer diseases only a minor part of the malignant cells will be in a proliferativestate, and consequently these drugs will exert a concomitant damage on rapidly proliferating benigntissue as well. A number of toxins possess an ability to kill cells in all states independently of whetherthey are benign or malignant. Such toxins can only be used as chemotherapeutics if they can betargeted selectively against the tumors. Examples of such toxins are mertansine, calicheamicins andthapsigargins, which all kill cells at low micromolar or nanomolar concentrations. Advanced prodrugconcepts enabling targeting of these toxins to cancer tissue comprise antibody-directed enzymeprodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), lectin-directed enzymeactivated prodrug therapy (LEAPT), and antibody-drug conjugated therapy (ADC), which will bediscussed in the present review. The review also includes recent examples of protease-targetingchimera (PROTAC) for knockdown of receptors essential for development of tumors. In addition,targeting of toxins relying on tumor-overexpressed enzymes with unique substrate specificity willbe mentioned.

AB - Many cancer diseases, e.g., prostate cancer and lung cancer, develop very slowly. Commonchemotherapeutics like vincristine, vinblastine and taxol target cancer cells in their proliferating states.In slowly developing cancer diseases only a minor part of the malignant cells will be in a proliferativestate, and consequently these drugs will exert a concomitant damage on rapidly proliferating benigntissue as well. A number of toxins possess an ability to kill cells in all states independently of whetherthey are benign or malignant. Such toxins can only be used as chemotherapeutics if they can betargeted selectively against the tumors. Examples of such toxins are mertansine, calicheamicins andthapsigargins, which all kill cells at low micromolar or nanomolar concentrations. Advanced prodrugconcepts enabling targeting of these toxins to cancer tissue comprise antibody-directed enzymeprodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), lectin-directed enzymeactivated prodrug therapy (LEAPT), and antibody-drug conjugated therapy (ADC), which will bediscussed in the present review. The review also includes recent examples of protease-targetingchimera (PROTAC) for knockdown of receptors essential for development of tumors. In addition,targeting of toxins relying on tumor-overexpressed enzymes with unique substrate specificity willbe mentioned.

KW - Faculty of Health and Medical Sciences

KW - Prodrugs

KW - Medicinal chemistry

KW - Chemotherapy

KW - Natural products

KW - review article

U2 - 10.3390/molecules26051292

DO - 10.3390/molecules26051292

M3 - Journal article

C2 - 33673582

VL - 26

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 5

M1 - 1292

ER -

ID: 257415333